Dr. Geoffrey S. Ginsburg Joins VisEn Medical's Scientific Advisory Board

VisEn Medical, Inc.

Dr. Geoffrey S. Ginsburg Joins VisEn Medical's Scientific Advisory Board

December 7, 2006

Heritage in Genomic Profiling and Molecular Medicine Tightly Linked with VisEn's Molecular Imaging Technology Platforms and Development Programs

Woburn, MA December 7, 2006 VisEn Medical, Inc., a leader in fluorescence in vivo imaging of biologic and molecular activities from research through medicine, today announced that Geoffrey S. Ginsburg, M.D., Ph.D. has joined its Scientific Advisory Board.

Dr. Ginsburg is Professor of Medicine and Pathology and Director of the Center for Genomic Medicine at Duke Universitys Institute for Genome Sciences & Policy. Dr. Ginsburgs work centers on the identification and application of predictive biomarkers in developing and applying novel therapies and for improved research and clinical medicine.

VisEn's fluorescence imaging technologies provide the industrys most robust imaging performance in identifying, characterizing and quantifying a range of biomarkers in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. By imaging these disease-related biological activities in vivo, VisEn's technology platforms enable expanded areas of research, more efficient drug development, and truly tailored clinical medicine into the future.

Kirtland G. Poss, President and Chief Executive Officer of VisEn commented on the announcement,

Dr. Ginsburgs deep heritage and expertise in genomics, biomarkers, pharmaceutical development and personalized medicine builds directly into VisEn's mission of developing and applying fluorescence imaging technologies from in vivo research through clinical medicine. We are honored by his participation with VisEn and see this as yet another key foundation for our companys leadership in clinically directed molecular imaging."

Dr. Ginsburg stated, "The future of clinical medicine will be built around linked understandings, readouts and treatments of disease-related biomarkers in patient populations. VisEn's real-time in vivo imaging of biologic and molecular processes is playing an increasingly central role in basic research and drug development today, and there is a close parallel between these approaches and the advanced molecular profiling work being carried out at our center.

By bringing together the industry experts and leaders in the fields of genomics, biomarkers, imaging and therapeutic intervention, we will work to produce new approaches to pharmaceutical development and personalized medicine that will have a truly positive impact on healthcare delivery, added Dr. Ginsburg. I look forward to collaborating even more deeply with VisEn's leading Scientific Advisory Board to further advance this promising new area of medicine."

Prior to his academic career, Dr. Ginsburg was Director of Cardiovascular Disease and Vice President of Molecular and Personalized Medicine at Millennium Pharmaceuticals. In these roles, he was responsible for Millenniums personalized medicine initiatives to develop biomarkers for disease and pharmacogenomic strategies for therapeutics and their implementation in the drug development process. His responsibilities also included translational research efforts and strategic academic alliances required to integrate genomics into the practice of medicine.

About VisEn Medical, Inc.

VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and Harvard Medical School. VisEn is developing todays highest performing fluorescence molecular imaging technology platforms, from research through medicine. VisEn also works directly with its partners to design ranges of tailored probes and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group. For further information please visit www.visenmedical.com

Contact:

Kirtland G. Poss (corporate)
President and CEO
VisEn Medical, Inc.
781-932-6875 X 301

Bryan P. Murphy or Donna LaVoie
LaVoie Group
781.596.0200 X 105/103
bmurphy@lavoiegroup.com or dlavoie@lavoiegroup.com